Showing 1 - 20 of 20 Items
Showing 1 - 20 of 20 Items
Sort By: Relevance
Journal Article
|Research
2025-04-23 • PLOS Global Public Health
2025-04-23 • PLOS Global Public Health
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médec...
Journal Article
|Research
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health
BACKGROUND
New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...
Journal Article
|Research
2024-06-06 • Antimicrobial Agents and Chemotherapy
2024-06-06 • Antimicrobial Agents and Chemotherapy
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...
Conference Material
|Abstract
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
INTRODUCTION
Clinical trials are a cornerstone of medical innovation. Nonetheless, little information on the cost of conducting clinical trials is available, especially for clinical ...
Clinical trials are a cornerstone of medical innovation. Nonetheless, little information on the cost of conducting clinical trials is available, especially for clinical ...
Conference Material
|Slide Presentation
2024-05-16 • MSF Scientific Day International 2024
2024-05-16 • MSF Scientific Day International 2024
Journal Article
|Research
2024-02-01 • Lancet Respiratory Medicine
2024-02-01 • Lancet Respiratory Medicine
BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...
Conference Material
|Poster
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|Research
2022-12-22 • New England Journal of Medicine
2022-12-22 • New England Journal of Medicine
BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...
Journal Article
|Research
2022-12-07 • PLOS Global Public Health
2022-12-07 • PLOS Global Public Health
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...
Journal Article
|Pre-Print
2022-11-10 • medRxiv
2022-11-10 • medRxiv
INTRODUCTION
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...
Journal Article
|Research
2021-12-04 • Trials
2021-12-04 • Trials
BACKGROUND
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Addressing the global burden of multidrug-resistant tuberculosis (MDR-TB) requires identification of shorter, less toxic treatment regimens. Médecins Sans Frontières (MSF)...
Conference Material
|Video
2022-06-07 • MSF Scientific Days International 2022
2022-06-07 • MSF Scientific Days International 2022
No abstract available.
Conference Material
|Slide Presentation
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
Conference Material
|Slide Presentation
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|Abstract
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...
Drug-resistant tuberculosis (DR-TB) carries significant morbidity and mortality risk. Care of DR-TB in pregnancy is even more challenging. A recent meta-analysis examini...
Journal Article
|Research
2022-06-13 • Trials
2022-06-13 • Trials
BACKGROUND
Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...
Globally rifampicin-resistant tuberculosis disease affects around 460,000 people each year. Currently recommended regimens are 9-24 months duration, have poor efficacy and...
Conference Material
|Video
2022-06-10 • MSF Scientific Days International 2022
2022-06-10 • MSF Scientific Days International 2022
Conference Material
|Abstract
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
INTRODUCTION
Rifamipcin-resistant tuberculosis (RR-TB) affects around 465,000 people each year globally. Current treatment is of 9-20 months’ duration; is toxic and poorly efficaciou...
Rifamipcin-resistant tuberculosis (RR-TB) affects around 465,000 people each year globally. Current treatment is of 9-20 months’ duration; is toxic and poorly efficaciou...
Conference Material
|Slide Presentation
2022-05-11 • MSF Scientific Days International 2022
2022-05-11 • MSF Scientific Days International 2022
Conference Material
|Abstract
2021-05-19 • MSF Scientific Days International 2021: Research
2021-05-19 • MSF Scientific Days International 2021: Research
INTRODUCTION
Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...
Almost 500,000 people worldwide develop multidrug-resistant tuberculosis (MDR-TB) annually, with a treatment success rate of around 60%. Current treatment consists of up...